These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15013521)

  • 1. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
    Karp JE; Lancet JE
    Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W; Lebowitz PF; Prendergast GC
    Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
    Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
    Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyl transferase inhibitors: current developments and future perspectives.
    Eskens FA; Stoter G; Verweij J
    Cancer Treat Rev; 2000 Oct; 26(5):319-32. PubMed ID: 11006134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
    Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.
    Lebowitz PF; Sakamuro D; Prendergast GC
    Cancer Res; 1997 Feb; 57(4):708-13. PubMed ID: 9044849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD
    Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitors: mechanism and applications.
    Prendergast GC; Rane N
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.